The company
Phibro Animal Health Corporation
PAHC · Nasdaq
PAHC stood above a rising 150-day average in 28 of the last 52 weekly readings, and has been out of that trend for the last 24 weeks. It is 2.3% below that average now. Pharmaceuticals: 31% of its 74 stocks in an uptrend (−7 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Setting up
- Weeks in an uptrend
- out for 24
- Industry in uptrend
- 31% -7 in 4 wk
- Insider buys, 12 months
- $635K
- Insider sales, 12 months
- $52.4M
- Officials’ trades on record
- 0
- Institutions holding
- 193 (-42)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 28 of 52 weeks.
Pharmaceuticals: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| E. Thomas CorcoranDirector | bought | 10,000at $31.77 | 29 May 2026filed 2 Jun 2026 |
| Jack BendheimPresident and CEO | sold | 1,350at $47.59 | 7 May 2026filed 7 May 2026 |
| Jack BendheimPresident and CEO | sold | 1,149at $48.31 | 7 May 2026filed 7 May 2026 |
| Jack BendheimPresident and CEO | sold | 2,029at $49.19 | 7 May 2026filed 7 May 2026 |
| Jack BendheimPresident and CEO | sold | 5,634at $57.18 | 6 May 2026filed 7 May 2026 |
| Jack BendheimPresident and CEO | sold | 1,406at $58.13 | 6 May 2026filed 7 May 2026 |
| Jack BendheimPresident and CEO | sold | 6,264at $55.73 | 5 May 2026filed 7 May 2026 |
| Jack BendheimPresident and CEO | sold | 776at $56.37 | 5 May 2026filed 7 May 2026 |
| Jack BendheimPresident and CEO | sold | 5,805at $52.65 | 30 Apr 2026filed 30 Apr 2026 |
| Jack BendheimPresident and CEO | sold | 1,235at $53.32 | 30 Apr 2026filed 30 Apr 2026 |
| Jack BendheimPresident and CEO | sold | 4,002at $52.70 | 29 Apr 2026filed 30 Apr 2026 |
| Jack BendheimPresident and CEO | sold | 3,038at $53.21 | 29 Apr 2026filed 30 Apr 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| BlackRock, Inc.reduced · filed 7 Aug 2026 | 3,219,040$101.1M | -34,808−1.1% |
| FMR LLCadded · filed 13 Aug 2026 | 3,160,281$99.2M | +987,155+45.4% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 1,038,382$32.6M | +88,349+9.3% |
| MILLENNIUM MANAGEMENT LLCadded · filed 14 Aug 2026 | 936,701$29.4M | +880,882+1578.1% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 923,318$29.0M | +32,035+3.6% |
| GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026 | 657,350$20.6M | +52,702+8.7% |
| DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 2026 | 531,087$16.7M | +23,235+4.6% |
| VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 2026 | 508,486$16.0M | +18,144+3.7% |
| RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 2026 | 480,500$15.1M | -96,235−16.7% |
| CastleKnight Management LPadded · filed 14 Aug 2026 | 461,322$14.5M | +385,427+507.8% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.